Viking Therapeutics (VKTX) Other Working Capital Changes (2014 - 2026)

Viking Therapeutics has disclosed Other Working Capital Changes across 13 years of filings, most recently posting $10.7 million for Q2 2026.

• In Q2 2026, Other Working Capital Changes rose 110.96% year-over-year to $10.7 million; the TTM figure through Jun 2026 stood at -$3.3 million (down 121.03% YoY), while the FY2025 annual figure was $5.2 million, up 1265.7% from the prior year.
• Other Working Capital Changes came in at $10.7 million for Q2 2026 at Viking Therapeutics, up from -$4.6 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $10.7 million in Q2 2026 to a low of -$14.3 million in Q4 2025.
• Average Other Working Capital Changes over 5 years is $421277.8, with a median of $68500.0 recorded in 2023.
• Year-over-year, Other Working Capital Changes sank 2694.83% in 2024 and soared 6341.77% in 2025.
• Over 5 years, Other Working Capital Changes stood at $1.4 million in 2022, then tumbled by 95.95% to $58000.0 in 2023, then slumped by 2694.83% to -$1.5 million in 2024, then slumped by 848.7% to -$14.3 million in 2025, then surged by 175.19% to $10.7 million in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $10.7 million in Q2 2026, -$4.6 million in Q1 2026, and -$14.3 million in Q4 2025.